The RPA194 response depends on the cellular model. BMH-21 reduced RPA194 in U2OS cells, whereas RPMI-7951 melanoma cells retained RPA194 despite nucleolar reorganization. WS-1 normal fibroblasts also retained RPA194 under the tested conditions. These results limit generalization of RPA194 degradation across cell types. [2]
Comparative transcription elongation by purified Pol I, II and III
Biochemical assay · Purified Saccharomyces cerevisiae RNA polymerases I, II and III on a defined RNA:DNA scaffold [1]
BMH-21 delayed Pol I nucleotide addition and produced persistent intermediates consistent with pausing. Pol II showed no detectable effect under the tested conditions, while Pol III was modestly inhibited.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 μM BMH-21 as reported for the preincubation and figure condition
- Exposure duration
- 5 min preincubation; reaction time course 0.005–10 s
- Method
- Reconstituted multi-nucleotide addition; quenched-flow sampling and gel-resolved RNA intermediates
- Vehicle
- BMH-21 storage buffer: 0.1 M NaH2PO4, pH 6
- Reported limits
- Supplement not retrieved; final concentration after mixing not independently clarified beyond the main-text condition. Chemical form and lot characterization not specified in the read main-text methods.
Methods and source locations
Compound reported in the paper: BMH-21; Compound label in the paper: BMH-21; salt/form unspecified
Applies to the reported experimental material and model; does not establish clinical efficacy or validate any catalog lot.
Methods 2.1–2.3; Results 3.1–3.3; Figures 1–4 and captions; Discussion 4.1
Pol I versus Pol II/III elongation response: Globally fitted multi-nucleotide addition time courses; three independent reactions per condition — Results 3.1–3.3; Figures 1–4; Methods 2.2–2.3
Elongation-complex stability control
Biochemical assay · Purified S. cerevisiae Pol I, II or III elongation complexes [1]
BMH-21 did not measurably accelerate elongation-complex collapse in the tested high-salt assay.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 μM
- Exposure duration
- Time course shown in Figure 5; no exact endpoint inferred from plot
- Method
- RNase protection assay of elongation-complex collapse with 1 M KCl and 10 μM RNase A
- Vehicle
- Storage-buffer vehicle (Methods 2.2)
- Reported limits
- Exact time schedule is not transcribed from the plotted axis; supplement not retrieved.
Methods and source locations
Compound reported in the paper: BMH-21; Compound label in the paper: BMH-21; salt/form unspecified
Applies to the reported experimental material and model; does not establish clinical efficacy or validate any catalog lot.
Methods 2.4; Results 3.4; Figure 5A–C and caption
Fraction of elongation-complex collapse: RNase-sensitive 7-mer relative to total RNA; three independent reactions; plotted mean ± SD — Results 3.4; Figure 5A–C and caption; Methods 2.4
RPA194 loss and proteasome-blockade control in A375 cells
Cell-based study · Human A375 melanoma cells [2]
RPA194 loss followed rapid inhibition of nascent RNA synthesis. Proteasome inhibitors retained RPA194 but did not restore rRNA transcription, separating transcription arrest from protein loss.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 μM BMH-21
- Exposure duration
- 3 h for the principal protein/proteasome-blockade comparison; kinetic experiments at the indicated earlier times
- Method
- Western blotting, immunofluorescence, cycloheximide chase, uridine labeling
- Vehicle
- Control conditions as labeled in Figures 5 and 7; vehicle identity for these selected panels is not specified in the read captions
- Co-treatment
- Mechanistic controls: MG132 10 μM or lactacystin 2 μM, 30 min pretreatment, then 3 h BMH-21; not an anticancer combination-efficacy study
- Reported limits
- Supplemental cell-culture details and cycloheximide concentration not retrieved; no missing details inferred.
Methods and source locations
Compound reported in the paper: BMH-21; Compound label in the paper: BMH-21, chemical name specified in Experimental Procedures; no salt named
Applies to the reported experimental material and model; does not establish clinical efficacy or validate any catalog lot.
Results: BMH-21 Causes Loss of Pol I Catalytic Subunit RPA194; Inhibition of RPA194 Degradation does not Rescue Pol I Transcription; Figures 5A–C,E–H and 7A–D; Experimental Procedures
RPA194 protein abundance: Western blot and confocal microscopy; NCL/loading and untreated/inhibitor controls as shown — Figures 5A–C,G–H and 7A–B; corresponding Results and captions
Nascent rRNA synthesis despite RPA194 retention: 3H-uridine metabolic labeling and FUrd incorporation; Figure 7C–D controls — Figure 7C–D and caption; Results: Inhibition of RPA194 Degradation does not Rescue Pol I Transcription
Cell-dependent RPA194 response
Cell-based study · U2OS osteosarcoma, RPMI-7951 melanoma and WS-1 normal fibroblast cells [2]
RPA194 decreased in U2OS but remained resistant to loss in RPMI-7951; normal fibroblasts also showed no RPA194 loss under the tested conditions. RPMI-7951 nevertheless showed nucleolar reorganization.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 μM BMH-21
- Exposure duration
- Blots: U2OS and RPMI-7951, 1 and 3 h; WS-1, 3 and 6 h. Microscopy: WS-1, 8 h; RPMI-7951, 6 h (Figure 6A–D)
- Method
- Western blotting and nucleolar immunofluorescence
- Vehicle
- Untreated controls shown; NCL loading control
- Co-treatment
- Actinomycin D 50 ng/ml comparator in Figure 6A–B; comparator rather than cotreatment
- Reported limits
- Replicate number for Figure 6A–D is not specified in the read caption; SI not retrieved.
Methods and source locations
Compound reported in the paper: BMH-21; Compound label in the paper: BMH-21; no salt named
Applies to the reported experimental material and model; does not establish clinical efficacy or validate any catalog lot.
Results: Decrease in RPA194 Correlates with Loss of Cancer Cell Survival; Figure 6A–D and caption
RPA194 abundance and nucleolar localization: Western blot with NCL control; microscopy for RPMI-7951 — Figure 6A–D and caption; Results: Decrease in RPA194 Correlates with Loss of Cancer Cell Survival